Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in patients with hepatocellular carcinoma: A real-world cohort study.

Ming-Hao XuCheng HuangMei-Ling LiXiao-Dong ZhuChang-Jun TanJian Zhou Jia Fan Hui-Chuan Sun Ying-Hao Shen

Published in: Cancer medicine (2023)

Lenvatinib combined with anti-PD-1 antibody therapy was effective in patients with sufficient liver function reserve. Further study is needed to improve therapeutic efficacy and AE management in patients with Child-Pugh class B or ALBI grade 2/3.

Keyphrases

mental health
stem cells
bone marrow
cell therapy